CA19-9 as a Potential Target for Radiolabeled Antibody-Based Positron Emission Tomography of Pancreas Cancer.
CA19-9 as a Potential Target for Radiolabeled Antibody-Based Positron Emission Tomography of Pancreas Cancer.
复制标题
DOI：
10.1155/2011/834515
复制
发表时间：
2011
期刊：
影响因子：
--
通讯作者：
Tomlinson JS
中科院分区：
文献类型：
--
作者：
Girgis MD;Olafsen T;Kenanova V;McCabe KE;Wu AM;Tomlinson JS
介绍。胰腺癌的敏感和特异性成像对于准确诊断、分期和治疗是必要的。绝大多数胰腺癌表达碳水化合物肿瘤抗原 CA19-9。本研究的目的是确定使用放射性标记的抗 CA19-9 抗体靶向 CA19-9 进行胰腺癌成像的潜力。方法。使用流式细胞术对人胰腺癌细胞系进行 CA19-9 定量。将完整的鼠抗 CA19-9 单克隆抗体用正电子发射放射性核素 (Iodine-124) 标记，并注射到携带抗原阳性和阴性异种移植物的小鼠中。注射后连续时间间隔（72小时、96小时、120小时）进行MicroPET/CT。测量血液和肿瘤中的放射性，以提供图像的客观确认。结果。通过流式细胞术检测抗原表达，结果显示阳性细胞系有大约 1.3 × 106 CA19-9 抗原，阴性细胞系没有表达。使用碘 124 标记的抗 CA19-9 mAb 进行的胰腺异种移植成像显示，平均肿瘤与血液比率为 5，阳性与阴性肿瘤比率为 20。结论。我们展示了放射性标记的抗 CA19-9 抗体对抗原阳性异种移植物的体内靶向。这些数据证明了实现基于抗 CA19-9 抗体的胰腺癌正电子发射断层扫描的潜力。
Introduction. Sensitive and specific imaging of pancreas cancer are necessary for accurate diagnosis, staging, and treatment. The vast majority of pancreas cancers express the carbohydrate tumor antigen CA19-9. The goal of this study was to determine the potential to target CA19-9 with a radiolabeled anti-CA19-9 antibody for imaging pancreas cancer. Methods. CA19-9 was quantified using flow cytometry on human pancreas cancer cell lines. An intact murine anti-CA19-9 monoclonal antibody was labeled with a positron emitting radionuclide (Iodine-124) and injected into mice harboring antigen positive and negative xenografts. MicroPET/CT were performed at successive time intervals (72 hours, 96 hours, 120 hours) after injection. Radioactivity was measured in blood and tumor to provide objective confirmation of the images. Results. Antigen expression by flow cytometry revealed approximately 1.3 × 106 CA19-9 antigens for the positive cell line and no expression in the negative cell line. Pancreas xenograft imaging with Iodine-124-labeled anti-CA19-9 mAb demonstrated an average tumor to blood ratio of 5 and positive to negative tumor ratio of 20. Conclusion. We show in vivo targeting of our antigen positive xenograft with a radiolabeled anti-CA19-9 antibody. These data demonstrate the potential to achieve anti-CA19-9 antibody based positron emission tomography of pancreas cancer.